BiotechTube

Mazdutide + Placebo

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Use Disorder

Conditions

Alcohol Use Disorder

Trial Timeline

Feb 6, 2025 → Aug 1, 2026

NCT ID
NCT06817356

About Mazdutide + Placebo

Mazdutide + Placebo is a phase 2 stage product being developed by Eli Lilly for Alcohol Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06817356. Target conditions include Alcohol Use Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Alcohol Use Disorder were approved

Approved (11) Terminated (2) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06817356Phase 2Recruiting

Competing Products

20 competing products in Alcohol Use Disorder

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47